Sanofi India Limited Cash Flow Conversion Efficiency
Sanofi India Limited cash flow conversion efficiency. Based on the latest financial reports, Sanofi India Limited (SANOFI) has a cash flow conversion efficiency ratio of 0.585x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs4.38 Billion ≈ $47.40 Million USD) by net assets (Rs7.49 Billion ≈ $81.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sanofi India Limited (2004–2025)
Cash flow conversion efficiency of Sanofi India Limited from 2004 to 2025. This chart illustrates how Sanofi India Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sanofi India Limited (SANOFI) share price today for real-time trading data and today's change.
Sanofi India Limited Cash Flow Conversion Ratio Explained
Sanofi India Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sanofi India Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanofi India Limited ranked by their cash flow conversion efficiency. Also see SANOFI market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SK Networks Co Ltd
KO:001740
|
-0.189x |
|
Sparekassen Sjaelland-Fyn A/S
CO:SPKSJF
|
0.107x |
|
Clinica Baviera
MC:CBAV
|
0.146x |
|
Yutong Optical
SHE:300790
|
0.026x |
|
Corsair Gaming Inc
NASDAQ:CRSR
|
0.045x |
|
Silence Therapeutics PLC
NASDAQ:SLN
|
0.039x |
|
Clairvest Group Inc.
TO:CVG
|
0.032x |
|
Radius Recycling, Inc.
NASDAQ:RDUS
|
0.006x |
Annual Cash Flow Conversion Efficiency for Sanofi India Limited (2004–2025)
The table below shows the annual cash flow conversion efficiency of Sanofi India Limited from 2004 to 2025. Review how much free cash does Sanofi India Limited generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Rs7.49 Billion ≈ $81.02 Million |
Rs4.51 Billion ≈ $48.76 Million |
0.602x | +12.23% |
| 2024-12-31 | Rs8.61 Billion ≈ $93.07 Million |
Rs4.62 Billion ≈ $49.91 Million |
0.536x | +136.29% |
| 2023-12-31 | Rs10.15 Billion ≈ $109.79 Million |
Rs2.30 Billion ≈ $24.92 Million |
0.227x | -27.38% |
| 2022-12-31 | Rs12.76 Billion ≈ $137.97 Million |
Rs3.99 Billion ≈ $43.12 Million |
0.313x | +24.47% |
| 2021-12-31 | Rs22.26 Billion ≈ $240.69 Million |
Rs5.59 Billion ≈ $60.43 Million |
0.251x | -12.94% |
| 2020-12-31 | Rs21.19 Billion ≈ $229.16 Million |
Rs6.11 Billion ≈ $66.09 Million |
0.288x | +70.83% |
| 2019-12-31 | Rs24.42 Billion ≈ $264.13 Million |
Rs4.12 Billion ≈ $44.59 Million |
0.169x | +0.20% |
| 2018-12-31 | Rs22.19 Billion ≈ $240.00 Million |
Rs3.74 Billion ≈ $40.44 Million |
0.168x | -21.53% |
| 2017-12-31 | Rs20.26 Billion ≈ $219.15 Million |
Rs4.35 Billion ≈ $47.05 Million |
0.215x | +15.52% |
| 2016-12-31 | Rs17.36 Billion ≈ $187.70 Million |
Rs3.23 Billion ≈ $34.89 Million |
0.186x | +41.87% |
| 2015-12-31 | Rs16.27 Billion ≈ $175.97 Million |
Rs2.13 Billion ≈ $23.05 Million |
0.131x | -26.53% |
| 2014-12-31 | Rs14.86 Billion ≈ $160.69 Million |
Rs2.65 Billion ≈ $28.65 Million |
0.178x | -11.89% |
| 2013-12-31 | Rs13.47 Billion ≈ $145.64 Million |
Rs2.73 Billion ≈ $29.48 Million |
0.202x | -14.90% |
| 2012-12-31 | Rs12.04 Billion ≈ $130.22 Million |
Rs2.86 Billion ≈ $30.97 Million |
0.238x | +29.53% |
| 2011-12-31 | Rs11.17 Billion ≈ $120.76 Million |
Rs2.05 Billion ≈ $22.17 Million |
0.184x | +42.45% |
| 2010-12-31 | Rs10.14 Billion ≈ $109.68 Million |
Rs1.31 Billion ≈ $14.14 Million |
0.129x | -12.71% |
| 2009-12-31 | Rs9.32 Billion ≈ $100.77 Million |
Rs1.38 Billion ≈ $14.88 Million |
0.148x | +2.28% |
| 2008-12-31 | Rs8.29 Billion ≈ $89.66 Million |
Rs1.20 Billion ≈ $12.95 Million |
0.144x | -1.97% |
| 2007-12-31 | Rs7.07 Billion ≈ $76.44 Million |
Rs1.04 Billion ≈ $11.26 Million |
0.147x | -27.73% |
| 2006-12-31 | Rs6.08 Billion ≈ $65.78 Million |
Rs1.24 Billion ≈ $13.40 Million |
0.204x | -32.31% |
| 2005-12-31 | Rs5.24 Billion ≈ $56.65 Million |
Rs1.58 Billion ≈ $17.05 Million |
0.301x | +77.53% |
| 2004-12-31 | Rs4.22 Billion ≈ $45.62 Million |
Rs715.33 Million ≈ $7.74 Million |
0.170x | -- |
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targoci… Read more